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Background
Amyloid cardiomyopathy is a polymorphic condition
with heterogeneous prognosis. Whereas AL amyloid car-
diomyopathy is the most frequent type of amyloid cardio-
pathy, transthyretin (TTR) amyloidosis is often under
diagnosed. TTR gene sequencing may be easily per-
formed although usually used after a histological proof of
amyloidosis is obtained. We conducted a prospective
study to evaluate the interest of TTR gene sequencing in
hypertrophic cardiomyopathy with suspicion of amyloi-
dosis before obtaining a histological proof of amyloidosis.
Methods
All patients referred for hypertrophic cardiomyopathy
between January 2014 and April 2015 with suspicion of
amyloidosis on echocardiography or cardiac MRI were
screened with light chain dosage, protein electrophoresis
and C-reactive protein dosage. When these exams were
normal, they were included in the study and underwent
TTR gene sequencing.
Results
Eight patients were included in the study, 7 men and 1
woman, median age at the time of inclusion 74 years.
All patients had clinical signs of congestive heart failure
with elevated NT-proBNP levels. No familial history was
noted. Among them, 4 patients, all from carribean ori-
gin, were diagnosed as having hereditary TTR cardiac
amyloidosis by sequencing of the TTR gene. These 4
patients had hypertrophic cardiomyopathy with altered
diastolic and systolic function, diagnosed respectively 7,
3, 2 years and six months before. Previous exams had
eliminated ischemic and valvular cardiomyopathy. Echo-
cardiographic study revealed increase of left ventricular
wall thickness predominant on septum wall with shiny
appearance. LV ejection fraction was between 35 and
50%. Two out the 4 patients underwent cardiac MRI
which showed diffuse delayed gadolinium enhancement
suggestive of amyloidosis. As all the patients included in
the study, these 4 patients did not have monoclonal
gammapathy and light chain dosage was normal. Trans-
thyretin sequencing revealed the presence of a missense
mutation Val122Ile (c.424 G>A) in these 4 patients. One
of the patients underwent a cardiac transplantation and
pathological examination confirmed amyloid cardiopa-
thy. Only 1 other patient had a confirmation of amyloid
deposit after an extensive work-up (patient #8, see
below).
Among the 8 patients, 8 had minor salivary gland
biopsy which revealed presence of amyloidosis deposits
in only 1 (patient #8, with a Val122Ile TTR mutation), 3
had abdominal fat aspiration (normal in all), 2 under-
went rectal mucosal biopsy (normal in all). Among the
4 patients who did not have a TTR mutation, 3 under-
went a endomyocardial biopsy to confirm the amyloid
nature of the cardiopathy which was positive in all 3.
Final diagnosis was AA amyloidosis for one, senile TTR
for one and non-typed amyloidosis for the last one.
Conclusion
TTR sequencing is a specific, non-invasive way to diag-
nose TTR amyloid cardiomyopathy and should be consid-
ered after exclusion of alternative causes of hypertrophic
cardiopathy.
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